Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
复制标题
DOI：
10.1126/scitranslmed.abn8057
复制
发表时间：
2022-03-23
影响因子：
17.1
通讯作者：
Liu SL
中科院分区：
文献类型：
--
作者：
Evans JP;Zeng C;Carlin C;Lozanski G;Saif LJ;Oltz EM;Gumina RJ;Liu SL
SARS-CoV-2疫苗效力的减弱，加上对疫苗诱导的免疫力产生抗性的变异体的不断出现，重新引发了关于是否需要加强疫苗剂量的争论。为了解决这一问题，我们检测了接种SARS-CoV-2 mRNA疫苗的卫生保健工作者（HCW）对五种主要SARS-CoV-2变体（D 614 G、Alpha（B.1.1.7）、Beta（B.1.351）、Delta（B.1.617.2）和Omicron（B.1.1.529））刺突蛋白的中和抗体应答。在接种前、首次接种后3周、第二次接种后1个月和第二次接种后6个月采集血清样本。在所有四个时间点检测到针对Omicron假病毒的最小中和抗体滴度，包括大多数SARS-CoV-2突破性感染的患者。尽管SARS-CoV-2感染促进了疫苗应答，但在第二次mRNA疫苗接种后1至6个月，针对所有其他携带变异刺突蛋白的假病毒的中和抗体滴度急剧下降。此外，mRNA-1273疫苗接种的HCW表现出比BNT 162 b2疫苗接种的HCW高约两倍的中和抗体滴度。总之，这些结果表明抗体介导的对SARS-CoV-2变体的保护可能减弱，这取决于先前的感染状态和接受的mRNA疫苗。他们还表明，Omicron变体刺突蛋白几乎可以完全逃避仅两个mRNA疫苗剂量的接受者中引起的中和抗体。两剂mRNA疫苗诱导的SARS-CoV-2特异性中和抗体在6个月后减弱，但在突破感染后增加。
The waning efficacy of SARS-CoV-2 vaccines, combined with the continued emergence of variants resistant to vaccine-induced immunity, has reignited debate over the need for booster vaccine doses. To address this, we examined the neutralizing antibody response against the spike protein of five major SARS-CoV-2 variants, D614G, Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529), in health care workers (HCWs) vaccinated with SARS-CoV-2 mRNA vaccines. Serum samples were collected pre-vaccination, three weeks post-first vaccination, one month post-second vaccination, and six months post-second vaccination. Minimal neutralizing antibody titers were detected against Omicron pseudovirus at all four time points, including for a majority of patients who had SARS-CoV-2 breakthrough infections. Neutralizing antibody titers against all other variant spike protein-bearing pseudoviruses declined dramatically from one to six months after the second mRNA vaccine dose, although SARS-CoV-2 infection boosted vaccine responses. Additionally, mRNA-1273-vaccinated HCWs exhibited about two-fold higher neutralizing antibody titers than BNT162b2-vaccinated HCWs. Together these results demonstrate possible waning of antibody-mediated protection against SARS-CoV-2 variants that is dependent on prior infection status and the mRNA vaccine received. They also show that the Omicron variant spike protein can almost completely escape from neutralizing antibodies elicited in recipients of only two mRNA vaccine doses. SARS-CoV-2-specific neutralizing antibodies induced by two doses of mRNA vaccine wane after six months but increase after breakthrough infection.
登录
查看更多内容
影响因子：
8.8
作者：
Yu J;Li M;Wilkins J;Ding S;Swartz TH;Esposito AM;Zheng YM;Freed EO;Liang C;Chen BK;Liu SL
通讯作者：
Liu SL
影响因子：
7.8
作者：
Bignucolo A;Scarabel L;Mezzalira S;Polesel J;Cecchin E;Toffoli G
通讯作者：
Toffoli G
影响因子：
64.8
作者：
Plante JA;Liu Y;Liu J;Xia H;Johnson BA;Lokugamage KG;Zhang X;Muruato AE;Zou J;Fontes-Garfias CR;Mirchandani D;Scharton D;Bilello JP;Ku Z;An Z;Kalveram B;Freiberg AN;Menachery VD;Xie X;Plante KS;Weaver SC;Shi PY
通讯作者：
Shi PY
DOI：
10.1016/s0140-6736(21)02183-8
发表时间：
2021-10-16
期刊：
Lancet (London, England)
影响因子：
--
作者：
Tartof SY;Slezak JM;Fischer H;Hong V;Ackerson BK;Ranasinghe ON;Frankland TB;Ogun OA;Zamparo JM;Gray S;Valluri SR;Pan K;Angulo FJ;Jodar L;McLaughlin JM
通讯作者：
McLaughlin JM
影响因子：
64.8
作者：
Mlcochova P;Kemp SA;Dhar MS;Papa G;Meng B;Ferreira IATM;Datir R;Collier DA;Albecka A;Singh S;Pandey R;Brown J;Zhou J;Goonawardane N;Mishra S;Whittaker C;Mellan T;Marwal R;Datta M;Sengupta S;Ponnusamy K;Radhakrishnan VS;Abdullahi A;Charles O;Chattopadhyay P;Devi P;Caputo D;Peacock T;Wattal C;Goel N;Satwik A;Vaishya R;Agarwal M;Indian SARS-CoV-2 Genomics Consortium (INSACOG);Genotype to Phenotype Japan (G2P-Japan) Consortium;CITIID-NIHR BioResource COVID-19 Collaboration;Mavousian A;Lee JH;Bassi J;Silacci-Fegni C;Saliba C;Pinto D;Irie T;Yoshida I;Hamilton WL;Sato K;Bhatt S;Flaxman S;James LC;Corti D;Piccoli L;Barclay WS;Rakshit P;Agrawal A;Gupta RK
通讯作者：
Gupta RK